Hepatitis C virus-specific T cell responses against conserved regions in recovered patients

被引:7
作者
Klade, C. S. [1 ]
Kubitschke, A. [2 ]
Stauber, R. E. [4 ]
Meyer, M. F. [2 ,3 ]
Zinke, S.
Wiegand, J. [2 ]
Zauner, W.
Aslan, N. [2 ]
Lehmann, M. [3 ]
Cornberg, M. [2 ]
Manns, M. P. [2 ]
Reisner, P.
Wedemeyer, H. [2 ]
机构
[1] Intercell AG, T Cell Epitope Identificat Program, A-1030 Vienna, Austria
[2] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[3] Jugendanstalt Hameln, Hameln, Germany
[4] Med Univ Graz, Dept Internal Med, Div Gastroenterol & Hepatol, Graz, Austria
关键词
Vaccination; Hepatitis C; Interferon; T cell responses; PROTECTIVE IMMUNITY; CROSS-REACTIVITY; PEPTIDE-VACCINE; INFECTION; THERAPY; ESCAPE; CD8; IMMUNOGENICITY; PERSISTENCE; REINFECTION;
D O I
10.1016/j.vaccine.2009.02.088
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
For the design of peptide-based vaccines against the hepatitis C virus it is essential to acquire more information on frequently recognized epitopes in patients with successful immune control of HCV in the context of different HLA types. A matrix approach using 393 15mer peptides from conserved HCV regions overlapping by 13 amino acids was applied in 52 HCV-recovered individuals. Candidate peptides were further tested in two independent laboratories. 38 peptides induced IFN-gamma responses in ELISPOT assays including 15 previously unknown epitopes. There was no particular immune dominance as only five peptides were recognized by more than three individuals. Seven out of 14 peptides tested in more detail could be confirmed to be immunogenic using ELISPOT and cytotoxicity assays. While only 33% of HCV-recovered individuals recognized recombinant HCV proteins, 81% of individuals tested positive in the matrix approach (p<0.001). The strength, frequency and breadth of HCV-specific T cell responses were similar in spontaneously recovered patients than in interferon-recovered patients. In conclusion (i) we identified novel HCV epitopes in conserved regions, (ii) confirmed the inter-individual diversity of HCV-specific T cell responses and (iii) found no significant differences in HCV-specific T cell responses between spontaneously recovered and IFN-recovered patients. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3099 / 3108
页数:10
相关论文
共 53 条
[1]   The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection [J].
Barnes, E ;
Harcourt, G ;
Brown, D ;
Lucas, M ;
Phillips, R ;
Dusheiko, G ;
Klenerman, P .
HEPATOLOGY, 2002, 36 (03) :743-754
[2]   Differential CD4+ and CD8+ T-cell responsiveness in hepatitis C virus infection [J].
Chang, KM ;
Thimme, R ;
Melpolder, JJ ;
Oldach, D ;
Pemberton, J ;
Moorhead-Loudis, J ;
McHutchison, JG ;
Alter, HJ ;
Chisari, FV .
HEPATOLOGY, 2001, 33 (01) :267-276
[3]   ISOLATION OF A CDNA CLONE DERIVED FROM A BLOOD-BORNE NON-A, NON-B VIRAL-HEPATITIS GENOME [J].
CHOO, QL ;
KUO, G ;
WEINER, AJ ;
OVERBY, LR ;
BRADLEY, DW ;
HOUGHTON, M .
SCIENCE, 1989, 244 (4902) :359-362
[4]   Cellular immune selection with hepatitis C virus persistence in humans [J].
Cox, AL ;
Mosbruger, T ;
Mao, Q ;
Liu, Z ;
Wang, XH ;
Yang, HC ;
Sidney, J ;
Sette, A ;
Pardoll, D ;
Thomas, DL ;
Ray, SC .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (11) :1741-1752
[5]   Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C [J].
Cramp, ME ;
Rossol, S ;
Chokshi, S ;
Carucci, P ;
Williams, R ;
Naoumov, NV .
GASTROENTEROLOGY, 2000, 118 (02) :346-355
[6]   Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses [J].
Draenert, R ;
Altfeld, M ;
Brander, C ;
Basgoz, N ;
Corcoran, C ;
Wurcel, AG ;
Stone, DR ;
Kalams, SA ;
Trocha, A ;
Addo, MM ;
Goulder, PJR ;
Walker, BD .
JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 275 (1-2) :19-29
[7]   Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees [J].
Elmowalid, Gamal A. ;
Qiao, Ming ;
Jeong, Sook-Hyang ;
Borg, Brian B. ;
Baumert, Thomas F. ;
Sapp, Ronda K. ;
Hu, Zongyi ;
Murthy, Krishna ;
Liang, T. Jake .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (20) :8427-8432
[8]   The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes [J].
Erickson, AL ;
Kimura, Y ;
Igarashi, S ;
Eichelberger, J ;
Houghton, M ;
Sidney, J ;
McKinney, D ;
Sette, A ;
Hughes, AL ;
Walker, CM .
IMMUNITY, 2001, 15 (06) :883-895
[9]   LACK OF PROTECTIVE IMMUNITY AGAINST REINFECTION WITH HEPATITIS-C VIRUS [J].
FARCI, P ;
ALTER, HJ ;
GOVINDARAJAN, S ;
WONG, DC ;
ENGLE, R ;
LESNIEWSKI, RR ;
MUSHAHWAR, IK ;
DESAI, SM ;
MILLER, RH ;
OGATA, N ;
PURCELL, RH .
SCIENCE, 1992, 258 (5079) :135-140
[10]   Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects [J].
Firbas, Christa ;
Jilma, Bernd ;
Tauber, Erich ;
Buerger, Vera ;
Jelovcan, Sandra ;
Lingnau, Karen ;
Buschle, Michael ;
Frisch, Jurgen ;
Klade, Christoph S. .
VACCINE, 2006, 24 (20) :4343-4353